 |
|
|
| |
Efficacy, Change in MELD Score, and Safety by Baseline MELD Score in Patients With Compensated Cirrhosis Receiving
Ombitasvir/Paritaprevir/r and Dasabuvir Plus Ribavirin in the Phase 3 TURQUOISE-II Trial
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Ira Jacobson1, TM Welzel2, Hugo E Vargas3, Marcos Pedrosa4, Norah Terrault5, Douglas Dieterich6, Fredric D Gordon7, Kris V Kowdley8, Guy Neff 4*, Ran Liu4, Juan Carlos Lopez-Talavera4*, Stefan Zeuzem2
1Weill Cornell Medical College, New York, New York, United States; 2JW Goethe University, Frankfurt, Germany; 3Mayo Clinic Arizona, Phoenix, Arizona, United States; 4AbbVie Inc., North Chicago, Illinois, United States; 5University of California San Francisco, San Francisco, California, United States;
6Mount Sinai School of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States; 7Lahey Hospital & Medical Center, Burlington, Massachusett s, United States; 8Liver Care Network, Swedish Medical Center, Seatt le, Washington, United States
|
| |
|
|
|
|
|
